Heparin and the peritoneal membrane

Peritoneal Dialysis International

Volumn 29, Issue 1, 2009, Pages 16-19

  Margetts, Peter ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTITHROMBIN; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; THROMBIN; TINZAPARIN; ANTICOAGULANT AGENT; DIALYSIS FLUID;

ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG BIOAVAILABILITY; DRUG INTERMITTENT THERAPY; DRUG PROTEIN BINDING; ENCAPSULATING PERITONEAL SCLEROSIS; GLUCOSE ABSORPTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INDWELLING CATHETER; LONG TERM CARE; MEMBRANE DAMAGE; NEPHROSCLEROSIS; NONHUMAN; NOTE; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; THROMBOCYTE AGGREGATION; ULTRAFILTRATION; VASODILATATION; WOUND HEALING; ANIMAL; DRUG COMBINATION; DRUG EFFECT; METABOLISM; METHODOLOGY; PERITONEAL DISEASE; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; DIALYSIS SOLUTIONS; DRUG COMBINATIONS; HEPARIN; HUMANS; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; THROMBOSIS;

EID: 65349174512     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902900102     Document Type: Note

References (29)

1. Schilte MN, Loureiro J, Keuning ED, ter Wee PM, Celie JWAM, Beelen RHJ, et al. Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Dial Int 2009; 29:26-35.
2. Lindahl U. 'Heparin' - from anticoagulant drug into the new biology. Glycoconj J 2000; 17:597-605.
3. Linhardt RJ. 2003 CLaude S. Hudson Award Address in Carbohydrate Chemistry. Heparin: structure and activity. J Med Chem 2003; 46:2551-64.
4. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007; 33: 688-94.
5. Niers TM, KLerk CP, DiNisio M, Van Noorden CJ, Buller HR, Reitsma PH, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61:195-207.
6. Mousa SA. Heparin, Low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007; 33:524-33.
7. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000; 30(Suppl 2):48-56.
8. Dzieciuchowicz L, Checinski P, Krauss H. Heparin reduces oxidative stressin the postoperative period. Med Sci Monit 2002; 8:CR657-60.
9. Hawari FI, Shykoff BE, Izzo JL Jr. Heparin attenuates norepinephrine-induced venoconstriction. Vasc Med 1998; 3:95-100.
10. De Vriese AS, Mortier S, Lameire NH. Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis. Perit Dial Int 2001; 21(Suppl 3):S354-6.
11. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66:2437-45.
12. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17:2591-8.
13. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound heaLing. J Thromb Haemost 2006; 4:932-9.
14. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S19-29.
15. Manalaysay MT, Kumano K, Hyodo T, Sakai T. Inhibition of mesothelial cell growth and protein synthesis by heparin. Adv Perit Dial 1995; 11:239-42.
16. Tsai TJ, Yen CJ, Fang CC, Yang CC, Lee PH, Yen TS. Effect of intraperitoneally administered agents on human peritoneal mesothelial ceLL growth. Nephron 1995; 71:23-8.
17. Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16:669-71.
18. Bazargani F, Albrektsson A, Yanyapour N, Braide M. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int 2005; 25:394-404.
19. De Vriese AS, Mortier S, Cornelissen M, Palmans E, Vanacker NJ, Leyssens A, et al. The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 2002; 22:566-72.
20. Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den Born J. Improvement of a chronic rat model for peritoneal dialysis by using heparin-coated catheters. Adv Perit Dial 2004; 20:150-4.
21. Kim YL, Cho S, Kim JC, Cho DK, Kim YJ, Larm 0, et al. Effect in a rat model of heparinized peritoneal dialysis catheters on bacterial colonization and the healing of the exit site. Perit Dial Int 2001; 21(Suppl 3):S357-8.
22. Sjoland JA, Smith PR, Jespersen J, Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis'patients. Nephrol Dial Transplant 2004; 19:1264-8.
23. Sjoland JA, Pedersen RS, Jespersen J, Gram J. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005; 100: c105-10.
24. Mizuiri S, Miyata S, Sakai K, Kobayashi M, Miyagi M, Nakanishi T, et al. Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD. Perit Dial Int 1999; 19:361-5.
25. Ponce SP, Barata JD, Santos JR. Interference of heparin with peritoneal solute transport. Nephron 1985; 39:47-9.
26. Demirkan F, Akarsu M, Sifil A, Tutucu KN. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients. Nephron 2002; 91:162-3.
27. GoelS, Misra M, Saran R, Khanna R. The rationale for, and role of, heparin in peritoneal dialysis. Adv Perit Dial 1998; 14:111-15.
28. Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S, Houghton JB, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43:531-7.
29. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358:2457-67.